Targeting voltage-gated calcium channels for the treatment of neuropathic pain: a review of drug development

Bibliography

• Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron 2006;52:77-92
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O'Connor AB, Audette J, Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85:S3-14
   PubMed Web of Science ®Google Scholar
• Attal N, Cruccu G, Haanpaa M, Efns guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006;13:1153-69
   PubMed Web of Science ®Google Scholar
• Williams JA, Day M, Heavner JE. Ziconotide: an update and review. Expert Opin Pharmacother 2008;9:1575-83
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Takahara A. Recent updates of n-type calcium channel blockers with therapeutic potential for neuropathic pain and stroke. Curr Top Med Chem 2009;9:377-95
   PubMed Web of Science ®Google Scholar
• Bear B, Asgian J, Termin A, Zimmermann N. Small molecules targeting sodium and calcium channels for neuropathic pain. Curr Opin Drug Discov Devel 2009;12:543-61
   PubMed Web of Science ®Google Scholar
• Catterall WA, Striessnig J, Snutch TP, International union of pharmacology. Xl. Compendium of voltage-gated ion channels: calcium channels. Pharmacol Rev 2003;55:579-81
   PubMed Web of Science ®Google Scholar
• Gray AC, Raingo J, Lipscombe D. Neuronal calcium channels: splicing for optimal performance. Cell Calcium 2007;42:409-17
   PubMed Web of Science ®Google Scholar
• Tringham E, Snutch TP. Structure, function, and modulation of neuronal voltage-gated ion channels. Wiley; Hoboken, N.J.; 2009
   Google Scholar
• McGivern JG, McDonough SI. Voltage-gated calcium channels as targets for the treatment of chronic pain. Curr Drug Targets CNS Neurol Disord 2004;3:457-78
   PubMedGoogle Scholar
• Zamponi GW, Feng ZP, Zhang L, Scaffold-based design and synthesis of potent n-type calcium channel blockers. Bioorg Med Chem Lett 2009;19:6467-72
   PubMed Web of Science ®Google Scholar
• Ohnami S, Tanabe M, Shinohara S, Role of voltage-dependent calcium channel subtypes in spinal long-term potentiation of c-fiber-evoked field potentials. Pain 2011;152:623-31
   PubMed Web of Science ®Google Scholar
• Dubel SJ, Starr TV, Hell J, Molecular cloning of the alpha-1 subunit of an omega-conotoxin-sensitive calcium channel. Proc Natl Acad Sci USA 1992;89:5058-62
   PubMed Web of Science ®Google Scholar
• Kerr LM, Filloux F, Olivera BM, Autoradiographic localization of calcium channels with [125i]omega-conotoxin in rat brain. Eur J Pharmacol 1988;146:181-3
   PubMed Web of Science ®Google Scholar
• Heinke B, Balzer E, Sandkuhler J. Pre- and postsynaptic contributions of voltage-dependent ca2+ channels to nociceptive transmission in rat spinal lamina i neurons. Eur J Neurosci 2004;19:103-11
   PubMed Web of Science ®Google Scholar
• Malmberg AB, Yaksh TL. Voltage-sensitive calcium channels in spinal nociceptive processing: blockade of n- and p-type channels inhibits formalin-induced nociception. J Neurosci 1994;14:4882-90
   PubMed Web of Science ®Google Scholar
• Holz GG IV, Dunlap K, Kream RM. Characterization of the electrically evoked release of substance P from dorsal root ganglion neurons: methods and dihydropyridine sensitivity. J Neurosci 1988;8:463-71
   PubMed Web of Science ®Google Scholar
• Maggi CA, Tramontana M, Cecconi R, Neurochemical evidence for the involvement of n-type calcium channels in transmitter secretion from peripheral endings of sensory nerves in guinea pigs. Neurosci Lett 1990;114:203-6
   PubMed Web of Science ®Google Scholar
• Smith MT, Cabot PJ, Ross FB, The novel n-type calcium channel blocker, am336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance p release in rat spinal cord slices. Pain 2002;96:119-27
   PubMed Web of Science ®Google Scholar
• Gruner W, Silva LR. Omega-conotoxin sensitivity and presynaptic inhibition of glutamatergic sensory neurotransmission in vitro. J Neurosci 1994;14:2800-8
   PubMed Web of Science ®Google Scholar
• Altier C, Zamponi GW. Targeting ca2+ channels to treat pain: T-type versus n-type. Trends Pharmacol Sci 2004;25:465-70
   PubMed Web of Science ®Google Scholar
• Sabido-David C, Faravelli L, Salvati P. The therapeutic potential of na+ and ca2+ channel blockers in pain management. Expert Opin Investig Drugs 2004;13:1249-61
   PubMed Web of Science ®Google Scholar
• Winquist RJ, Pan JQ, Gribkoff VK. Use-dependent blockade of cav2.2 voltage-gated calcium channels for neuropathic pain. Biochem Pharmacol 2005;70:489-99
   PubMed Web of Science ®Google Scholar
• Yaksh TL. Calcium channels as therapeutic targets in neuropathic pain. J Pain 2006;7:S13-30
   PubMed Web of Science ®Google Scholar
• Olivera BM. Conus peptides: biodiversity-based discovery and exogenomics. J Biol Chem 2006;281:31173-7
   PubMed Web of Science ®Google Scholar
• Terlau H, Olivera BM. Conus venoms: a rich source of novel ion channel-targeted peptides. Physiol Rev 2004;84:41-68
   PubMed Web of Science ®Google Scholar
• Leipold E, Hansel A, Olivera BM, Molecular interaction of delta-conotoxins with voltage-gated sodium channels. FEBS Lett 2005;579:3881-4
   PubMed Web of Science ®Google Scholar
• Li RA, Tomaselli GF. Using the deadly mu-conotoxins as probes of voltage-gated sodium channels. Toxicon 2004;44:117-22
   PubMed Web of Science ®Google Scholar
• Shon KJ, Olivera BM, Watkins M, Mu-conotoxin PIIIA, a new peptide for discriminating among tetrodotoxin-sensitive na channel subtypes. J Neurosci 1998;18:4473-81
   PubMed Web of Science ®Google Scholar
• Nielsen KJ, Schroeder T, Lewis R. Structure-activity relationships of omega-conotoxins at n-type voltage-sensitive calcium channels. J Mol Recognit 2000;13:55-70
   PubMed Web of Science ®Google Scholar
• Scott DA, Wright CE, Angus JA. Actions of intrathecal omega-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat. Eur J Pharmacol 2002;451:279-86
   PubMed Web of Science ®Google Scholar
• Bingham JP, Mitsunaga E, Bergeron ZL. Drugs from slugs–past, present and future perspectives of omega-conotoxin research. Chem Biol Interact 2010;183:1-18
   PubMed Web of Science ®Google Scholar
• Bulaj G. Integrating the discovery pipeline for novel compounds targeting ion channels. Curr Opin Chem Biol 2008;12:441-7
   PubMed Web of Science ®Google Scholar
• Staats PS, Yearwood T, Charapata SG, Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or aids: a randomized controlled trial. JAMA 2004;291:63-70
   PubMed Web of Science ®Google Scholar
• Wallace MS, Charapata SG, Fisher R, The ziconotide nonmalignant pain study 96-002 group (2006), intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation 2006;9:75-86
   PubMed Web of Science ®Google Scholar
• Rauck RL, Wallace MS, Leong MS, A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage 2006;31:393-406
   PubMed Web of Science ®Google Scholar
• Webster LR, Fisher R, Charapata S, Long-term intrathecal ziconotide for chronic pain: an open-label study. J Pain Symptom Manage 2009;37:363-72
   PubMed Web of Science ®Google Scholar
• Wallace MS, Rauck R, Fisher R, Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial. Anesth Analg 2008;106:628-37, table of contents
   PubMed Web of Science ®Google Scholar
• Ellis DJ, Dissanayake S, McGuire D, Continuous intrathecal infusion of ziconotide for treatment of chronic malignant and nonmalignant pain over 12 months: a prospective, open-label study. Neuromodulation 2008;11:40-4
   PubMed Web of Science ®Google Scholar
• Deer T, Krames ES, Hassenbusch SJ, Polyanalgesic consensus conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromudulation 2007;10:300-28
   PubMed Web of Science ®Google Scholar
• Rauck RL, Wallace MS, Burton AW, Intrathecal ziconotide for neuropathic pain: a review. Pain Pract 2009;9:327-37
   PubMed Web of Science ®Google Scholar
• Bowersox SS, Gadbois T, Singh T, Selective n-type neuronal voltage-sensitive calcium channel blocker, snx-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain. J Pharmacol Exp Ther 1996;279:1243-9
   PubMed Web of Science ®Google Scholar
• Malmberg AB, Yaksh TL. Effect of continuous intrathecal infusion of omega-conopeptides, n-type calcium-channel blockers, on behavior and antinociception in the formalin and hot-plate tests in rats. Pain 1995;60:83-90
   PubMed Web of Science ®Google Scholar
• Prialt package insert.
   Google Scholar
• Wallace MS, Kosek PS, Staats P, Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. Pain Med 2008;9:271-81
   PubMed Web of Science ®Google Scholar
• Wallace MS, Rauck RL, Deer T. Ziconotide combination intrathecal therapy: rationale and evidence. Clin J Pain 2010;26:635-44
   PubMed Web of Science ®Google Scholar
• Mao J. N-type calcium channel blocker for pain treatment. Pain Med 2010;11:153
   PubMed Web of Science ®Google Scholar
• McGivern JG. Targeting n-type and t-type calcium channels for the treatment of pain. Drug Discov Today 2006;11:245-53
   PubMed Web of Science ®Google Scholar
• Kolosov A, Goodchild CS, Cooke I. Cnsb004 (leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain. Pain Med 2010;11:262-73
   PubMed Web of Science ®Google Scholar
• Raffa RB, Pergolizzi JV Jr. The evolving understanding of the analgesic mechanism of action of flupirtine. J Clin Pharm Ther 2010; [Epub ahead of print]
   Web of Science ®Google Scholar
• Berecki G, Motin L, Haythornthwaite A, Analgesic (omega)-conotoxins CVIE and CVIF selectively and voltage-dependently block recombinant and native n-type calcium channels. Mol Pharmacol 2010;77:139-48
   PubMed Web of Science ®Google Scholar
• Baell JB, Duggan PJ, Forsyth SA, Synthesis and biological evaluation of nonpeptide mimetics of omega-conotoxin gvia. Bioorg Med Chem 2004;12:4025-37
   PubMed Web of Science ®Google Scholar
• Andersson A, Baell JB, Duggan PJ, Omega-conotoxin gvia mimetics based on an anthranilamide core: effect of variation in ammonium side chain lengths and incorporation of fluorine. Bioorg Med Chem 2009;17:6659-70
   PubMed Web of Science ®Google Scholar
• Neuromed, merck give up on new pain drug. Philadelphia business journal. August 2007. Available from: http://wwwizjournalscom/philadelphia/stories/2007/08/06/daily17html [Last accesed April 2011]
   Google Scholar
• Murakami M, Nakagawasai O, Fujii S, Antinociceptive effect of cilnidipine, a novel n-type calcium channel antagonist. Brain Res 2000;868:123-7
   PubMed Web of Science ®Google Scholar
• Koganei H, Shoji M, Iwata S. Suppression of formalin-induced nociception by cilnidipine, a voltage-dependent calcium channel blocker. Biol Pharm Bull 2009;32:1695-700
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Niwa S, Ohno S, Structure-activity relationship study of 1,4-dihydropyridine derivatives blocking n-type calcium channels. Bioorg Med Chem Lett 2006;16:798-802
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Niwa S, Ohno S, The structure-activity relationship study on 2-, 5-, and 6-position of the water soluble 1,4-dihydropyridine derivatives blocking n-type calcium channels. Bioorg Med Chem Lett 2008;18:4813-16
   PubMed Web of Science ®Google Scholar
• Meng G, Wu N, Zhang C, Analgesic activity of zc88, a novel n-type voltage-dependent calcium channel blocker, and its modulation of morphine analgesia, tolerance and dependence. Eur J Pharmacol 2008;586:130-8
   Google Scholar
• Tyagarajan S, Chakravarty PK, Park M, A potent and selective indole n-type calcium channel (ca(v)2.2) blocker for the treatment of pain. Bioorg Med Chem Lett 2011;21:869-73
   PubMed Web of Science ®Google Scholar
• Abbadie C, McManus OB, Sun SY, Analgesic effects of a substituted n-triazole oxindole (trox-1), a state-dependent, voltage-gated calcium channel 2 blocker. J Pharmacol Exp Ther 2010;334:545-55
   PubMed Web of Science ®Google Scholar
• Carbone E, Lux HD. A low voltage-activated, fully inactivating ca channel in vertebrate sensory neurones. Nature 1984;310:501-2
   PubMed Web of Science ®Google Scholar
• Nowycky MC, Fox AP, Tsien RW. Three types of neuronal calcium channel with different calcium agonist sensitivity. Nature 1985;316:440-3
   PubMed Web of Science ®Google Scholar
• Perez-Reyes E. Molecular physiology of low-voltage-activated t-type calcium channels. Physiol Rev 2003;83:117-61
   PubMed Web of Science ®Google Scholar
• Talley EM, Cribbs LL, Lee JH, Differential distribution of three members of a gene family encoding low voltage-activated (t-type) calcium channels. J Neurosci 1999;19:1895-911
   PubMed Web of Science ®Google Scholar
• Bourinet E, Alloui A, Monteil A, Silencing of the cav3.2 t-type calcium channel gene in sensory neurons demonstrates its major role in nociception. EMBO J 2005;24:315-24
   PubMed Web of Science ®Google Scholar
• Jagodic MM, Pathirathna S, Nelson MT, Cell-specific alterations of t-type calcium current in painful diabetic neuropathy enhance excitability of sensory neurons. J Neurosci 2007;27:3305-16
   PubMed Web of Science ®Google Scholar
• Todorovic SM, Jevtovic-Todorovic V, Mennerick S, Ca(v)3.2 channel is a molecular substrate for inhibition of t-type calcium currents in rat sensory neurons by nitrous oxide. Mol Pharmacol 2001;60:603-10
   PubMed Web of Science ®Google Scholar
• Bourinet E, Zamponi GW. Voltage gated calcium channels as targets for analgesics. Curr Top Med Chem 2005;5:539-46
   PubMed Web of Science ®Google Scholar
• Nelson MT, Woo J, Kang HW, Reducing agents sensitize c-type nociceptors by relieving high-affinity zinc inhibition of t-type calcium channels. J Neurosci 2007;27:8250-60
   PubMed Web of Science ®Google Scholar
• Jagodic MM, Pathirathna S, Joksovic PM, Upregulation of the t-type calcium current in small rat sensory neurons after chronic constrictive injury of the sciatic nerve. J Neurophysiol 2008;99:3151-6
   PubMed Web of Science ®Google Scholar
• Dogrul A. Reversal of experimental neuropathic pain by t-type calcium channel blockers. Pain 2003;105:159-68
   PubMed Web of Science ®Google Scholar
• Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain 2004;109:150-61
   PubMed Web of Science ®Google Scholar
• Barton ME, Eberle EL, Shannon HE. The antihyperalgesic effects of the t-type calcium channel blockers ethosuximide, trimethadione, and mibefradil. Eur J Pharmacol 2005;521:79-85
   PubMed Web of Science ®Google Scholar
• Martin RL, Lee JH, Cribbs LL, Mibefradil block of cloned t-type calcium channels. J Pharmacol Exp Ther 2000;295:302-8
   PubMed Web of Science ®Google Scholar
• Hord AH, Denson DD, Chalfoun AG, The effect of systemic zonisamide (zonegran) on thermal hyperalgesia and mechanical allodynia in rats with an experimental mononeuropathy. Anesth Analg 2003;96:1700-6, table of contents
   PubMed Web of Science ®Google Scholar
• Tanabe M, Murakami T, Ono H. Zonisamide suppresses pain symptoms of formalin-induced inflammatory and streptozotocin-induced diabetic neuropathy. J Pharmacol Sci 2008;107:213-20
   PubMed Web of Science ®Google Scholar
• Atli A, Dogra S. Zonisamide in the treatment of painful diabetic neuropathy: a randomized, double-blind, placebo-controlled pilot study. Pain Med 2005;6:225-34
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Hashimoto K, Tsuji S. Successful use of zonisamide for central poststroke pain. J Pain 2004;5:192-4
   PubMed Web of Science ®Google Scholar
• Jarvis SE, Zamponi GW. Trafficking and regulation of neuronal voltage-gated calcium channels. Curr Opin Cell Biol 2007;19:474-82
   PubMed Web of Science ®Google Scholar
• Xiao W, Boroujerdi A, Bennett GJ, Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit. Neuroscience 2007;144:714-20
   PubMed Web of Science ®Google Scholar
• Li CY, Zhang XL, Matthews EA, Calcium channel alpha2delta1 subunit mediates spinal hyperexcitability in pain modulation. Pain 2006;125:20-34
   PubMed Web of Science ®Google Scholar
• Luo ZD, Calcutt NA, Higuera ES, Injury type-specific calcium channel alpha 2 delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J Pharmacol Exp Ther 2002;303:1199-205
   PubMed Web of Science ®Google Scholar
• Boroujerdi A, Zeng J, Sharp K, Calcium channel alpha-2-delta-1 protein upregulation in dorsal spinal cord mediates spinal cord injury-induced neuropathic pain states. Pain 2011;152:649-55
   PubMed Web of Science ®Google Scholar
• Attal N, Cruccu G, Baron R, Efns guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113-e88
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O'Connor AB, Backonja M, Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 2007;132:237-51
   PubMed Web of Science ®Google Scholar
• FDA approves once-daily gabapentin for postherpetic neuralgia. Available from: http://wwwmedscapecom/viewarticle/736872?src=emailthis [Last Accessed April 2011]
   Google Scholar
• Field MJ, Li Z, Schwarz JB. Ca2+ channel alpha2-delta ligands for the treatment of neuropathic pain. J Med Chem 2007;50:2569-75
   PubMed Web of Science ®Google Scholar
• Snutch TP. Targeting chronic and neuropathic pain: the n-type calcium channel comes of age. NeuroRx 2005;2:662-70
   PubMedGoogle Scholar
• Belardetti F, Zamponi GW. Linking calcium-channel isoforms to potential therapies. Curr Opin Investig Drugs 2008;9:707-15
   PubMed Web of Science ®Google Scholar
• Belardetti F, Tringham E, Eduljee C, A fluorescence-based high-throughput screening assay for the identification of t-type calcium channel blockers. Assay Drug Dev Technol 2009;7:266-80
   PubMed Web of Science ®Google Scholar
• Barrow JC, Duffy JL. Voltage-gated calcium channel antagonists for the central nervous system. In: John EM. editor. Annual reports in medicinal chemistry. Volume 45. Academic Press; 2010. p. 2-18
   Google Scholar